Sichuan HISCO Pharmaceutical Co., Ltd
Sichuan Haisco Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Haisco Pharmaceutical Group Co., Ltd., located in the Cross-Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu, covering an area of 33,266 m2 with a registered capital of RMB 130 million. Sichuan Haisco is oriented as a R&D-driven manufacturing base, which involves process development, intermediate experiment scale-up, production of clinical samples and commercial production of raw materials and auxiliary materials in various fields such as cardiovascular, anti-infection, digestive system, mental system, liver disease and metabolic system.
Sichuan Haisco has a group of professional talents, Dr. Haijun ZHANG, General Manager, and Dr. Haifeng ZHANG, Deputy General Manager and others, have rich experience in drug R&D and production management at home and abroad. There are more than 300 personnel of such as R&D, quality and manufacture in the base, including 38% of R&D personnel, 14% of quality personnel, and bachelor degree or above accounted for 58%.
Sichuan Haisco owns a variety of functional laboratories, including such as synthesis, preparation, analysis, and has dozens of R&D and testing devices and equipment including such as photochemical reactors, nuclear magnetic resonance, XRD, CAD, liquid chromatography, gas chromatography, preparative liquid chromatography, multifunctional granulator. Currently, the projects under development include several innovative drug projects such as HSK7653, HSK16149 and several generic drug projects.
Sichuan Haisco has a sound production management team, and has established a relatively well-organized quality management system, which has passed China GMP inspection for multiple times. Currently, it has several production lines such as tablets, capsules, granules, ointments and drug substances that meet the GMP requirements of China, including the production capacity of 31 tons/year for non-sterile drug substances, production line capacities of 110 million tablets/year for tablets, 110 million capsules/year for capsules and 18 million bags/year for granules.
Sichuan Haisco is constantly improving the level of cGMP management and strives to enter the US market by passing US FDA inspection.
Liaoning Haisco Pharmaceutical Co., Ltd
Liaoning Haisco Pharmaceutical Co., Ltd. was established on May 19, 2005, with a registered capital of RMB 780 million. In July 2011, it was recognized as a national high-tech enterprise covering an area of about 76,000 m2, and has built more than 50,000 m2 of various workshops and supporting facilities that meet the national GMP standards of China. The company has 9 professional production lines for such as small-volume injections (including pre-filled syringes, non-terminally sterilized), lyophilized powder for injection (including hormones), powder for injection (cephalosporins), large-volume injections (including multi-layer co-extrusion infusion bags), drug substances. Among them, the multi-chamber bag infusion production line with international advanced level has been constructed, and Medium and Long Chain Fat Emulsion, Amino Acid (16) and Glucose (16%) Injection has obtained the first (exclusive) approval for the production of multi-chamber bag infusion productions in China, and the product has been marketed at the end of 2018, filling the blank of domestic multi-chamber bag infusion.
The company has always been focusing on the development of new products, the marketed and developed products cover numbers of therapeutic areas such as anti-infection, digestive system, hematological system, nervous system, and parenteral nutrition. As of June 2021, Liaoning Haisco Pharmaceutical Co., Ltd. has obtained 40 drug production approval numbers for 28 varieties, including Compound Vitamin for Injection (3), Medium and Long Chain Fat Emulsion Injection (C6-24), Compound Amino Acid Injection (18AA-VII), Dorasetron Mesylate Injection, Fat Emulsion, Amino Acid (17) and Glucose (11%) Injection, Palonosetron Hydrochloride Injection, as well as five new drug certificates such as Nalmefene Hydrochloride Injection, Dorasetron Mesylate Injection, Compound Vitamin for Injection (3), Arginine Glutamate Injection.